Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Perspectives
Our Leadership
Ethics & Compliance
Investors
My Library
Quintiles Files Registration Statement for Initial Public Offering
The Data Driven Difference – Planning & Design
Quintiles Unlocks Path for Digital Patient Engagement
The Data Driven Difference
The Future Healthcare Ecosystem
Strategic Planning and Design
Quintiles Infosario™
Publications by Quintiles Authors
Real-World and Late Phase Oncology Expertise: Stronger Evidence, Healthier Results
Merck Serono and Quintiles Announce Innovative Clinical Development Partnership
Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
Risk-based Approach to Monitoring: Deployment Insights and Lessons Learned
Risk-based Approach to Monitoring: The Future Roles of People, Process & Technology
Effectively Meet the New EU Pharmacovigilance Requirements
Planning for Success in Large Global Vaccine Studies
Quintiles Announces Pricing of Initial Public Offering